1. Home
  2. FOSL vs KPTI Comparison

FOSL vs KPTI Comparison

Compare FOSL & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FOSL
  • KPTI
  • Stock Information
  • Founded
  • FOSL 1984
  • KPTI 2008
  • Country
  • FOSL United States
  • KPTI United States
  • Employees
  • FOSL N/A
  • KPTI N/A
  • Industry
  • FOSL Consumer Specialties
  • KPTI Biotechnology: Pharmaceutical Preparations
  • Sector
  • FOSL Consumer Discretionary
  • KPTI Health Care
  • Exchange
  • FOSL Nasdaq
  • KPTI Nasdaq
  • Market Cap
  • FOSL 100.0M
  • KPTI 81.1M
  • IPO Year
  • FOSL 1993
  • KPTI 2013
  • Fundamental
  • Price
  • FOSL $1.54
  • KPTI $0.60
  • Analyst Decision
  • FOSL
  • KPTI Strong Buy
  • Analyst Count
  • FOSL 0
  • KPTI 4
  • Target Price
  • FOSL N/A
  • KPTI $5.00
  • AVG Volume (30 Days)
  • FOSL 228.1K
  • KPTI 840.0K
  • Earning Date
  • FOSL 03-12-2025
  • KPTI 02-19-2025
  • Dividend Yield
  • FOSL N/A
  • KPTI N/A
  • EPS Growth
  • FOSL N/A
  • KPTI N/A
  • EPS
  • FOSL N/A
  • KPTI N/A
  • Revenue
  • FOSL $1,223,954,000.00
  • KPTI $145,237,000.00
  • Revenue This Year
  • FOSL N/A
  • KPTI $4.47
  • Revenue Next Year
  • FOSL N/A
  • KPTI $7.35
  • P/E Ratio
  • FOSL N/A
  • KPTI N/A
  • Revenue Growth
  • FOSL N/A
  • KPTI N/A
  • 52 Week Low
  • FOSL $0.75
  • KPTI $0.53
  • 52 Week High
  • FOSL $2.61
  • KPTI $1.70
  • Technical
  • Relative Strength Index (RSI)
  • FOSL 39.03
  • KPTI 41.56
  • Support Level
  • FOSL $1.60
  • KPTI $0.53
  • Resistance Level
  • FOSL $1.80
  • KPTI $0.64
  • Average True Range (ATR)
  • FOSL 0.11
  • KPTI 0.05
  • MACD
  • FOSL -0.01
  • KPTI -0.00
  • Stochastic Oscillator
  • FOSL 5.71
  • KPTI 44.13

About FOSL Fossil Group Inc.

Fossil Group Inc is a design, innovation and distribution company in consumer fashion accessories. The products include traditional watches, smartwatches, jewelry, handbags, small leather goods, belts and sunglasses. The reportable segments are comprised of 1) Americas segment includes sales in Canada, Latin America and the United States. 2) Europe segment includes sales in European countries, the Middle East and Africa. 3) Asia segment includes sales in Australia, China, India, Indonesia, Japan, Malaysia, New Zealand, Singapore, South Korea and Thailand. Each reportable operating segment includes sales to wholesale and distributor customers, and sales through Company-owned retail stores and e-commerce activities based on the location of the selling entity.

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

Share on Social Networks: